禾元生物：公司120吨重组人白蛋白生产线预计2026年建成

Group 1 - The company has indicated that its 120-ton recombinant human albumin production line is expected to be completed by 2026, with new capacity dependent on equipment debugging and approval from the drug regulatory authority [2] - The company's drug, Ofumin®, is anticipated to be approved for market entry in July 2025, with steady progress in hospital access and distribution channel development [2] - There is currently a supply-demand imbalance in the market, indicating a strong demand for the company's products [2]